Biocytogen to Deliver 1 Oral and 3 Poster Presentations at PEGS EUROPE 2022, Introducing RenLite Platform, TCR-mimic Platform, and Antibody Assets
November 8, 2022
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced today that the company will present at the upcoming Protein & Antibody Engineering Summit (PEGS EUROPE) conference in Barcelona, Spain on November 14-16, 2022. Frank An, Ph.D., Senior Director of Antibody Therapeutics at Biocytogen, will give an oral presentation at 13:50-14:20 on Tuesday, November 15, introducing […]
37th SITC Annual Meeting 2022
November 3, 2022
Join us at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston, MA! Our booth will be open to greet visitors on November 10th and 11th at the Boston Exhibition and Convention Center! Stop by to chat with us (booth #743) to check out our latest model and service offerings. Whether you […]
Biocytogen to Present Progress of Antibody Assets and Five Fully Human Antibody Discovery Platforms at ChinaBio 2022
November 3, 2022
Biocytogen’s BD & Licensing team will attend and present at the upcoming ChinaBio virtual conference on November 8-11, 2022. The company will give an oral presentation with the title of “Introduction of Biocytogen’s pipeline assets, innovative fully human antibody RenMice platform and Project Integrum for antibody discovery against 1000+ potential targets”. The talk will introduce […]
30% OFF Antibody Discovery services!
November 1, 2022
Get started on your antibody discovery project as the year comes to a close! All projects* for the month of December will receive 30% OFF antibody discovery services using either Beacon-based or FACS-based screening technology! Both Beacon and FACS-based screening technologies can identify hundreds, or even thousands, of single B cells that generate antibodies to […]
Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence
November 1, 2022
YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in phase II multi-regional clinical trials sponsored by Eucure Biopharma for pancreatic cancer and melanoma in Australia, the US and China. ISU ABXIS intends to deploy YH003 sequence to develop tri-specific antibody for the treatment of […]
Festival of Biologics Basel 2022
October 27, 2022
Speaker: Qingcong Lin, CEO, Biocytogen Boston Corporation Date: Nov 3, 2022 Time: 12:20 PM CET/ 6:20 AM EDT Next-Generation Humanized Models Accelerate Antibody Discovery, Lead Characterization & Candidate Selection In this session, we will focus on NK Cell-based therapeutics, and will introduce several NK cell receptor humanized mouse models and tumor cell lines, as well as xenogeneic […]
Development History of Immunodeficient Mice and Their Research Applications
October 25, 2022
By John Charpentier, Ph.D. October 25, 2022 Since the characterization of the nude mouse in 1962, genetic mouse models of immunodeficiency have been increasingly developed, diversified, and utilized for both basic discovery research and preclinical studies of therapeutic candidates. Today, highly immunodeficient, genetically-engineered mouse models are invaluable tools for basic biomedical research, especially for the […]
Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy
October 18, 2022
BEIJING, China and FORT LAUDERDALE, FL., Oct. 18, 2022 (BUSINESS WIRE) – Eucure (Beijing) Biopharma Co., Ltd. (“Eucure”), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”), announced today that the company has entered into a worldwide licensing agreement with Syncromune, Inc. (“Syncromune”), a US-based clinical stage biopharmaceutical company, for the development and […]
Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022
October 17, 2022
Beijing, China, October 17, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November 2-4, 2022. Using advanced proprietary gene-editing technologies, Biocytogen has developed five proprietary fully human antibody discovery platforms: a RenMabTM-based monoclonal antibody platform, a RenLite®-based […]
AAPS Pharmsci 360® 2022
October 12, 2022
As a premiere provider of pharmacology services and tools that accelerate the pace of preclinical research, Biocytogen is thrilled to be an exhibitor at PharmSci 360®. Stop by booth #366 to meet our team, discuss a project, and learn more about how we can be a resource and asset to you. Representatives from the company’s management and business team […]
